Intuitive Surgical (ISRG) Stock Price, News & Analysis

Company Overview

Intuitive Surgical, Inc. develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures. Intuitive also offers the Ion endoluminal system for minimally invasive lung biopsy procedures, along with compatible instruments, accessories, digital technologies, training, and service programs.

Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical serves hospitals and healthcare providers in the United States and international markets. The company’s systems are supported by recurring sales of instruments, accessories, and services. David J. Rosa serves as chief executive officer, following Gary S. Guthart, who led the company for many years.

Key Stats

• Today's Range: $407.07 to $414.20
• 50-Day Range: $332.02 to $414.79
• 52-Week Range: $328.57 to $603.88
• Volume: 1.73 million shs
• Average Volume: 2.44 million shs
• Market Capitalization: $145.61 billion
• P/E Ratio: 47.21
• Dividend Yield: N/A
• Price Target: $508.68
• Consensus Rating: Moderate Buy

Intuitive Surgical Stock Analysis - MarketRank™

Intuitive Surgical scored higher than 87% of companies evaluated by MarketBeat, and ranked 55th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intuitive Surgical has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on no strong buy ratings, 22 buy ratings, 8 hold ratings, and 1 sell rating.

Upside Potential

Intuitive Surgical has a consensus price target of $508.68, representing about 23.9% upside from its current price of $410.56.

Amount of Analyst Coverage

Intuitive Surgical has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.97%

Earnings Growth

Earnings for Intuitive Surgical are expected to grow by 12.97% in the coming year, from $8.87 to $10.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intuitive Surgical is 47.01, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intuitive Surgical is 47.01, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.90.

Price to Earnings Growth Ratio

Intuitive Surgical has a PEG Ratio of 3.06. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Intuitive Surgical has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.31% of the float of Intuitive Surgical has been sold short.

Short Interest Ratio / Days to Cover

Intuitive Surgical has a short interest ratio ("days to cover") of 3.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intuitive Surgical has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intuitive Surgical does not currently pay a dividend.

Dividend Growth

Intuitive Surgical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.88

News Sentiment

Intuitive Surgical has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Intuitive Surgical this week, compared to 10 articles on an average week.

Search Interest

Only 45 people have searched for ISRG on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

MarketBeat Follows

29 people have added Intuitive Surgical to their MarketBeat watchlist in the last 30 days. This is an increase of 7% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Intuitive Surgical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,891,989.00 in company stock.

Percentage Held by Insiders

0.60% of the stock of Intuitive Surgical is held by insiders.

Percentage Held by Institutions

83.64% of the stock of Intuitive Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/16/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 10/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ISRG
• CIK: 1035267
• Web: www.intuitive.com
• Phone: (408) 523-2100
• Fax: 408-523-1390
• Employees: 17,021
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Intuitive Surgical: $508.68
• High Price Target: $685.00
• Low Price Target: $357.44
• Potential Upside/Downside: +23.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.68
• Research Coverage: 31 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.73
• Trailing P/E Ratio: 47.16
• Forward P/E Ratio: 46.45
• P/E Growth: 3.06
• Net Income: $2.86 billion
• Net Margins: 28.45%
• Pretax Margin: 34.49%
• Return on Equity: 16.91%
• Return on Assets: 14.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.96
• Quick Ratio: 3.91

Sales & Book Value

• Annual Sales: $10.06 billion
• Price / Sales: 14.46
• Cash Flow: $9.44 per share
• Price / Cash Flow: 43.67
• Book Value: $50.52 per share
• Price / Book: 8.16

Miscellaneous

• Outstanding Shares: 353,280,000
• Free Float: 351,158,000
• Market Cap: $145.56 billion
• Optionable: Optionable
• Beta: 1.47